Ju Dong Yang named medical director of the Liver Cancer Program Cedars-Sinai Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ju Dong Yang was named medical director of the Liver Cancer Program at Cedars-Sinai Cancer Center.

Ju Dong Yang is a liver cancer clinician-researcher who studies epidemiology, health disparities and outcomes, and biomarkers. His work focuses on early detection of liver cancer. 

As medical director, Yang will continue to address liver cancer and non-alcoholic fatty liver disease in high-risk populations. 

Yang intends to establish a multidisciplinary clinic that allows patients to receive care from multiple specialty providers at one location, increase the number of clinical trials of liver cancer treatments, and investigate biomarkers that will help predict treatment outcomes.

Yang will also begin community-based education initiatives that will better facilitate the accrual of clinical trials.  

Yang has completed fellowships in gastroenterology, hepatology, and transplant hepatology. He holds a master’s degree in clinical and translational research from the Mayo Clinic. 

Table of Contents

YOU MAY BE INTERESTED IN

Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 
Marking a new era of non-invasive medical interventions, the Northwell Health Cancer Institute is investing $1.2 million in the development of cutting-edge histotripsy technology to treat some liver cancer tumors without surgery. This innovative approach uses targeted ultrasound beams to create microbubbles within tumors, effectively disrupting and destroying diseased cells without the need for incisions.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login